401 related articles for article (PubMed ID: 29862290)
1. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Kotyla PJ
Biomed Res Int; 2018; 2018():7492904. PubMed ID: 29862290
[TBL] [Abstract][Full Text] [Related]
2. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada S; Kubo S; Iwata S; Tanaka Y
BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
[TBL] [Abstract][Full Text] [Related]
3. The emerging safety profile of JAK inhibitors in rheumatic disease.
Winthrop KL
Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461
[TBL] [Abstract][Full Text] [Related]
4. JAK-STAT inhibitors for the treatment of immunomediated diseases.
Serra López-Matencio JM; Morell Baladrón A; Castañeda S
Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
6. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
10. [JAK Inhibitors in Rheumatology].
Witte T
Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
[TBL] [Abstract][Full Text] [Related]
11. [JAK inhibitor].
Yamaoka K; Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
[TBL] [Abstract][Full Text] [Related]
12. Malignancy and Janus Kinase Inhibition.
Sivaraman P; Cohen SB
Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
[TBL] [Abstract][Full Text] [Related]
13. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
MacFarlane LA; Todd DJ
Int J Rheum Dis; 2014 May; 17(4):359-68. PubMed ID: 24460872
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
15. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Yiu ZZ; Warren RB
Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in psoriatic arthritis.
Wang TS; Tsai TF
Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
[TBL] [Abstract][Full Text] [Related]
19. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
20. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
